Euroz Hartleys has released a research note on Botanix Pharmaceuticals Ltd., maintaining a price target of $0.80. The report also mentions that President Trump's recent executive order on drug pricing will have "little to no impact" on Botanix or its product Sofdra™. More details can be found at https://bit.ly/BOT-AnalystNote-May2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.